Glucagon
Also known as: GlucaGen, Baqsimi
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
FDA-approved pancreatic peptide hormone involved in blood glucose rescue and diagnostic use.
Status
FDA Approved
Typical dose
Limited community data available
Researched for
Hypoglycemia emergency, blood sugar rescue
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
FDA approved - FDA-approved for specific uses with established human evidence
Use the tools
Stay current
Get updates on Glucagon
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- 29-amino-acid pancreatic hormone associated with raising blood glucose.
- Listed by the source as FDA approved for hypoglycemia and diagnostic contexts.
- Administration routes in the source include injection, intranasal delivery, and auto-injector formats.
- Community dose information is limited, while the source includes FDA-labeling context for emergency hypoglycemia use.
- Research focus is described around hypoglycemia rescue, blood glucose regulation, GCGR biology, and metabolic drug development.
How it's thought to work
Glucagon is reported to bind GCGR, a liver-focused G-protein-coupled receptor. Downstream signaling proceeds through Gs, adenylate cyclase, cAMP, and PKA. In the supplied mechanism description, this signaling promotes glycogenolysis and gluconeogenesis, including enzymes such as PEPCK and glucose-6-phosphatase, resulting in increased glucose release from the liver.
What the research shows
Where the research stands
The supplied evidence presents glucagon as an established hormone and FDA-approved clinical agent rather than an experimental . It notes severe hypoglycemia rescue as a settled use and describes newer formats such as nasal powder and stable liquid auto-injectors. Mechanistic research cited in the source centers on GCGR and PKA signaling control of hepatic glucose output. The source also links excess glucagon signaling with poorer glucose regulation in diabetes and notes current interest in GCGR activity within dual and triple metabolic drug research.
What it shows
✓ Human clinical evidence
FDA-approved for specific uses with established human evidence
△ Limitations
Use only according to approved labeling and qualified medical guidance.
Bottom line: FDA Approved - Hypoglycemia and diagnostic FDA Approved
Typical dosing
CommunityCommunity datasetLimited community data available
See research protocols
Range: See research dosing
Community dose information is sparse in the supplied source and points back to research protocols rather than a specific nonclinical pattern.
Research dosing
Indication-specificApproved for specific uses - study doses are indication-specific
Timing & administration
Best time to take
Morning
Follow specific protocol
Food recommendation
Take on empty stomach
Why this timing?
The source gives a general timing note for metabolic peptides, suggesting morning timing to align with daytime energy use; glucagon-specific timing should follow the relevant protocol context.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Nausea
- Vomiting
- Headache
- Hypertension
- Tachycardia
- Allergic reactions
- Rebound hypoglycemia
- Contraindicated with pheochromocytoma
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.